Selank dosage chart

Reconstitution steps

1. 1Draw 3mL of bacteriostatic water into a sterile syringe.
2. 2Inject the water slowly down the inside wall of the 10MG Selank vial.
3. 3Swirl gently until fully dissolved — do not shake.
4. 4Use a U-100 insulin syringe for accurate dosing.
5. 5Store reconstituted solution refrigerated at 2–8 °C, protected from light.

Spartan Peptides official protocol

Recommended: 200–600mcg, 1–2 times daily. Start low and titrate up based on individual response and goals. Swirl gently — do not shake. Inject subcutaneously.

• Mixing guide: mix 10MG Selank with 3mL BAC water.
• Concentration after mixing: 3.33 mg/mL (~33mcg per unit).
• Recommended dosage: 200mcg – 600mcg.
• Injection frequency: 1–2 times daily.
• Use an insulin syringe (U-100) for accurate dosing.

Reported research focus

Research purposes only. Premium quality. Built on legacy. Backed by science.

• Supports mood balance*
• Supports cognitive function*
• Helps reduce stress & anxiety*
• Promotes overall well-being*

Published Human Intranasal Selank Research

Human Selank research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.

The current manufacturer instruction describes a 0.15% nasal-drop product at 1.10 mg/mL, with two drops placed in each nasal passage three times daily for 14 days. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump.

Reference concentration: Mathematically, 10 mg brought to about 6.67 mL equals 1.10 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.

Nasal Spray Actuator Math

A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Pharmaceutical literature reports pump volumes from approximately 0.025 mL to 0.20 mL per spray. Use the manufacturer specification or a validated measurement for the exact device.

mcg per spray = (10,000 mcg / final volume in mL) x verified mL per spray

nominal sprays = final volume in mL / verified mL per spray

• Confirm the stated volume per full actuation for the specific pump.
• Follow the documented priming and repriming procedure.
• Record residual volume and tail-off near bottle exhaustion when estimating usable sprays.
• Keep pump orientation and actuation stroke consistent during the research procedure.

Important Notes

Small measurement and device details can materially change the amount delivered per spray.

• Use a measured final volume, not the bottle capacity mark alone.
• Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
• Prime and reprime exactly as specified for the pump, then record those actuations.
• Keep the bottle upright and use a complete, consistent stroke for each recorded spray.
• Treat the theoretical 50 or 100 sprays as nominal counts because priming and residual hold-up consume part of the volume.
• A 10 mg vial contains 10,000 mcg total. Calculate the complete peptide requirement before modeling any multi-day published protocol.
• Use a validated laboratory handling and stability plan for any custom multidose preparation.

How Intranasal Selank Research Works

Selank is a synthetic heptapeptide based on the tuftsin sequence. Human studies have examined anxiety-related clinical measures, leu-enkephalin metabolism, EEG response patterns, and functional brain connectivity after Selank exposure. Intranasal drops or solution are the delivery methods reported in the primary human research summarized on this page.

The vial calculation is concentration based. Dividing 10,000 mcg by the measured final volume gives mcg per mL. Multiplying that concentration by the verified pump output gives mcg per spray.

Human Research Findings and Observations

Selank findings should be read together with the population, amount, formulation, and study design.

• The 2008 comparative study reported similar anxiety-related effects for Selank and medazepam, with additional anti-asthenic and psychostimulant observations in the Selank group.
• In the 2012 GAD study, 40% of participants were classified as rapid responders during days 1 to 3, while 60% showed a gradual response pattern through day 14.
• The healthy-volunteer neuroimaging study examined functional connectivity after one intranasal Selank exposure rather than a repeated clinical course.
• The current manufacturer instruction lists unpleasant taste sensations and possible allergic reactions among reported adverse effects.
• Pump output, formulation, nasal condition, and administration technique can affect the delivered amount and deposition pattern.

Research Controls That Affect Nasal Delivery

Consistent technique improves the value of recorded research observations.

• Pump specification: Record the stated or measured mL per actuation.
• Priming status: Document first use, repriming, and any missed sprays.
• Actuation technique: Keep bottle orientation, stroke length, and stroke force consistent.
• Nasal condition: Record congestion, irritation, or other conditions that could affect deposition.
• Formulation details: Record the vehicle, final volume, concentration, container, and storage conditions.
• Actuation count: Track sprays from priming through final use to identify tail-off and residual volume.

Nasal Actuator Technique

Use a standardized device procedure so the recorded amount remains consistent across research observations.

• Inspect the labeled concentration and confirm the actuator output before use.
• Prime or reprime the pump according to the manufacturer instructions.
• Keep the bottle in the specified orientation and use one complete, smooth stroke.
• Record each actuation immediately, including priming sprays.
• Wipe the nozzle with a clean material appropriate for the device and replace the cap.
• Return the bottle to its documented storage condition after the research procedure.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Selank is for research use only and not intended for human consumption. Always consult qualified healthcare professionals before considering any peptide therapy.

Selank dosage FAQs